Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974100 | 0.90 | TRPV1 (0.51) | TRPV1SCN5ASCN9AMETAP2 | |
| SCHEMBL14430621 | 0.89 | TRPV1 (0.50) | TRPV1SCN5ASCN9AMETAP2 | |
| SCHEMBL4359689 | 0.83 | TRPV1 (0.45) | TRPV1METAP2 | |
| SCHEMBL4908258 | 0.81 | TRPV1 (0.67) | TRPV1 | |
| SCHEMBL27635443 | 0.80 | CYP2A6 (0.45) | TRPV1 | |
| SCHEMBL4355503 | 0.79 | PIK3CD (0.47) | TRPV1SCN5ASCN9AMETAP2 | |
| SCHEMBL4174480 | 0.76 | TRPV1 (0.54) | TRPV1SCN5ASCN9A | |
| SCHEMBL4911389 | 0.75 | TRPV1 (0.67) | TRPV1SCN5ASCN9A | |
| SCHEMBL4474506 | 0.75 | PIK3CD (0.49) | TRPV1METAP2 | |
| SCHEMBL11907725 | 0.75 | TRPV1 (0.52) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| CN-1726205-A | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | NEUROGEN CORP (US) | 2006-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR52 | TRPV1 279/4885SCN5A 860/4885SCN9A 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.